Teva’s New Copaxone Gaining Market Share Ahead Of Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.
You may also be interested in...
Emerging Markets Earnings: Teva Moves On With Russia, LatAm In Focus
Teva appears to have eased past a management shakeup and extended its lead in Copaxone with the company ready to expand in emerging markets as the next frontier, led by Russia and Latin America.
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.